The Tintina fault has triggered many more earthquakes than was thought — and a build-up of strain poses a hazard.

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Biogen’s $2B RTP expansion highlights a wave of growth in the Triangle, with billions in projects and thousands of jobs on ...

Quarterly Net Profit at Rs. 1.34 crore in June 2025 up 950.06% from Rs. 0.16 crore in June 2024. EBITDA stands at Rs. 1.34 ...

Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), ...

Fumarate therapies are equally effective among Black, Hispanic, Asian, and white people with relapsing forms of MS, a real-world study shows.

Coriolis Pharma, a pharmaceutical services company based in Germany, is investing $10 million to build a laboratory at Spark ...

Modernization of “manufacturing technologies and controls through further advanced automation and artificial intelligence” ...

ALS is a progressive and fatal neurological disorder with no known cure. A new clinic offering treatment raises alarms about ...